Tumor Cells In Ascitic Fluid Research Articles

Фенотипическое разнообразие макрофагов при раке яичников

Фенотипическое разнообразие макрофагов при раке яичников

Effect of metallic nanoparticles on tumor growth: In vivo study.

e15650 Background: The aim of the study was to assess the effect of metallic nanoparticles on growth of transplanted ascitic tumor sarcoma 37 in mice. Methods: Nanoparticles (NP) of transition metals were experimentally developed and kindly provided us by Prof. V.B. Borodulin. Ultradispersed metallic powders (NP Cu, NP Zn, NP Fe) 30-100 nm sized were dispersed by ultrasound in 0.85% NaCl before use and daily administrated intraperitoneally to tumor-bearing mice with ascitic sarcoma 37. Injections of NP 500 µl (10 µg/ml) were performed for 4 days, and 4 days after the completion of the course mice were sacrificed. The control group received 0.85% NaCl. Ascitic fluid volume was measured and living cells were counted. Results: In all the tumor-bearing mice the progression of ascites was noted: it was maximal in controls, less in animals having received NP Fe and NP Cu, minimal – in mice after injection of NP Zn. The volume of the latter was 0.78±0.31 ml in comparison with control data: 1.79±0.66 ml (p < 0.05); it was also less than in mice after administration of NP Cu (2.16±0.68 ml) and NP Fe (3.3±1.3 ml). Similar difference was seen in the amount of tumor cells in ascitic fluid: (1.67±0.5)х106/ml after the injection of NP Zn and (27.7±2.86)х106/мл in the control group. Effect of NP Cu and NP Fe was less pronounced than of NP Zn though obvious in spite of the noted tendency of the increase of the ascitic fluid volume. The most significant changes were observed when absolute amount of living tumor cells was counted per one mouse – it was minimal after NP Zn administration (0.636±0.2)х106/ml and maximal in the control group (23.98±10.5)х106/ml), i.e. only 2.6% of tumor cells had survived after NP Zn injection. Conclusions: Our results demonstrate that metallic NP were able to produce antitumor in vivo without any supplements like laser or hyperthermia: the effect was likely to depend upon the metal and was the highest in NP Zn compared to NP Cu and Fe.

Solitomab, an EpCAM/CD3 bispecific antibody (BiTE®), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo

Objectives: Chemotherapy-resistant ovarian cancer remains an incurable disease. Solitomab is a novel bispecific single-chain antibody that targets the epithelial antigen EpCAM on tumor cells and also contains a CD3-binding region. We evaluated the in vitro activity of solitomab against multiple primary chemotherapy-resistant epithelial ovarian carcinoma cell lines and malignant tumor cells in ascitic fluid.

Case Report: Detection and quantification of tumor cells in peripheral blood and ascitic fluid from a metastatic esophageal cancer patient using the CellSearch (®) technology.

Analysis of ascitic fluid should help to identify and characterize malignant cells in gastrointestinal cancer. However, despite a high specificity, the sensitivity of traditional ascitic fluid cytology remains insufficient, at around 60%. Since 2004 the CellSearch (®) technology has shown its advantages in the detection of circulating tumor cells (CTCs) in peripheral blood, which can perform an accurate diagnosis and molecular analysis at the same time. To our knowledge, no previous study has explored the potential utility of this technology for the detection and quantification of tumor cells in ascitic fluid samples. Herein we report a case of metastatic esophageal adenocarcinoma in a 70-year-old man presenting with dysphagia and a large amount of fluid in the peritoneal cavity. Analysis of a peripheral blood sample and ascites sample with the CellSearch (®) technology both revealed the presence of putative tumor cells that were positive for epithelial cell adhesion molecule (EpCAM) and cytokeratin (CK) expression. This study confirmed the hematogenous dissemination of esophageal cancer by the detection of circulating tumor cells in the peripheral blood, and is the first to demonstrate that tumor cells can be identified in ascitic fluid by using CellSearch (®) technology.

Abstract 1714: Chemoresistance in patients with papillary serous carcinoma of the ovary

Abstract The majority of patients with ovarian carcinoma present at an advanced stage, with metastatic disease throughout the peritoneal cavity. Therefore, patients commonly undergo platinum-based chemotherapy. Even though the initial response rates can be high, the majority of patients will have recurrent disease and the 5-year survival rate is only 10-20%. The human lung resistance protein (LRP) is a multidrug resistance protein that has been shown to be overexpressed in models of chemotherapy resistance, but has not been adequately explored in platinum-resistant epithelial ovarian cancer (EOC). The primary aim of this study was to compare LRP expression in the tumor cells from ascitic fluid with tumor cells from omental metastasis in chemotherapy-naïve patients with advanced EOC. The secondary aim was to explore possible mechanisms in which LRP might cause drug resistance. After IRB approval, patient ascites and metastatic implants were collected and evaluated for platinum sensitivity and expression of LRP, phospho-ERK, and AKT using western blots and immunohistochemistry (IHC). Both ascites and omental metastatic implants were treated with 50 uM carboplatin for 48 hours and cell viability was analyzed. LRP, phospho-ERK, and AKT were analyzed using IHC on samples treated with 50 uM carboplatin or phosphate buffered saline. Of 20 patients who had matched ascites and omental metastatic implants adequate for analysis, 4 were platinum resistant, 3 were platinum sensitive, and 13 displayed intermediate platinum sensitivity. Overall, the malignant cells in ascites were more resistant to carboplatin than the metastatic implants (p=0.001) and the malignant cells in ascites showed higher expression of LRP than the omental metastatic implants by IHC and western blotting. IHC and western blotting also demonstrated that the malignant cells in ascites had lower expression of phospho-ERK and higher expression of AKT than the metastatic implants. After treatment with 50 uM carboplatin, the platinum resistant patients had decrease in phospho-ERK and an increase in AKT versus the platinum sensitive patients who had an increase in phopho-ERK and a decrease in AKT and LRP. High expression of LRP in the tumor cells in ascitic fluid may indicate platinum resistance prior to initiation of platinum-based chemotherapy. Also, changes in phospho-ERK and AKT following platinum based therapy may indicate the extent of response of EOC to this therapy. Supported in part by the Kaleidoscope of Hope ovarian cancer foundation. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1714. doi:10.1158/1538-7445.AM2011-1714

Cytomorphology of adult granulosa cell tumor in ascitic fluid

Adult granulosa cell tumors (AGCT) are associated with ascites in 10% of the cases. Although these tumors form two per cent of all ovarian tumors, they may create a diagnostic challenge in cytologic preparations. The tumor cells are not readily shed in the fluid. A case of a 47-year-old woman with presence of granulosa tumor cells in ascitic fluid is presented. Because of its rarity, AGCTs can be confused with other ovarian tumors.

Ciliated ovarian adenocarcinoma cells in ascitic fluid cytology: Report of a case with immunocytochemical features

A case of ovarian serous adenocarcinoma presenting with ascitic fluid is reported. Cytology of the ascitic fluid showed the presence of cilia on most of malignant tumor cells. These tumor cells occurred singly; cilia usually appeared in unipolar locations. Immunocytochemical studies were performed on the ascitic fluid samples as well as tissue sections. CA19-9, CA125, CA50, and epithelial antigens were positive, while carcinoembryonic antigen was negative. The positive reactions were characteristic for cilia of the tumor cells. The findings also emphasize that positive reaction of these markers will usually exclude a noncommon epithelial tumor, but will not distinguish between benign and malignant ovarian tumors. Report of cilia-bearing tumor cells in ascitic fluid are few; no one, to the best of our knowledge, has previously documented the immunocytochemistry of these tumor cells.

Evolution of sarcoma 180 in mice infected with Trypanosoma cruzi.

Mice infected with Trypanosoma cruzi were challenged with 2x10[raised to the power of 6] cells of sarcoma 180 (ascite tumor) by i.p. route, on day seven post infection. Tumor development was followed by evaluation of weight gain, by measurement of ascitic fluid produced and enumeration of tumor cells in ascitic fluid. Infected mice were more resitant to tumor development as demonstrated by reduction in ascites formation and by reduction in the number of tumor cells in ascitic fluid, at different time intervals after tumor challenge. The number of peritoneal cells exsudated after tumor inoculation was greater in infected mice than in controls. This increased resitance of mice infected with T. cruzi to tumor development could be due to the action of macrophages activated by the infection and by the action of endotoxins absorbed from the gut or produced by the own parasite.